Is AstraZeneca Stock a Buy for Growth Investors?
Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark. And smaller companies that lack any approved drugs and have few drug candidates in their pipelines face a heightened risk of bankruptcy if things don't go their way.
This is why I'd advise most investors to consider only the most dominant and established pharmaceutical companies for their portfolios. British drugmaker (NASDAQ: AZN) is one such company. But should growth investors buy the stock now? Let's examine AstraZeneca in further detail to decide.
AstraZeneca's total revenue fell 4% year over year to $10.9 billion in the first quarter. But considering that the company sells its products throughout the world and the U.S. dollar has been more robust than usual against other currencies lately, this isn't quite the full picture. AstraZeneca's currency-neutral revenue was flat during the quarter.
Source Fool.com
